Antibacterial efficacy of eravacycline In Vivo against gram-positive and gram-negative organisms

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 5001-5005

  Monogue, Marguerite L ^a   Thabit, Abrar K ^a,b   Hamada, Yukihiro ^a,c   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERAVACYCLINE; LINEZOLID; MEROPENEM; TIGECYCLINE; VANCOMYCIN; 7-FLUORO-9-PYRROLIDINOACETAMIDO-6-DEMETHYL-6-DEOXYTETRACYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE; TETRACYCLINE DERIVATIVE; THIENAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CITROBACTER FREUNDII; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STAPHYLOCOCCUS AUREUS; TETRACYCLINES; THIENAMYCINS; VANCOMYCIN;

EID: 84979517906     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00366-16     Document Type: Article

References (23)

1. Boyle DP, Zembower TR. 2015. Epidemiology and management of emerging drug-resistant Gram-negative bacteria: extended-spectrum β-lactamases and beyond. Urol Clin North Am 42:493-505. http://dx.doi.org/10.1016/j.ucl.2015.05.005.
2. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. US Department of Health and Human Services, CDC, Atlanta, GA. Available at http://www.cdc.gov/drugresistance/threat-report-2013/.
3. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57:5548-5558. http://dx.doi.org/10.1128/AAC.01288-13.
4. Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA. 2012. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559-2564. http://dx.doi.org/10.1128/AAC.06187-11.
5. Cosgrove SE, Fowler VG, Jr. 2008. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46(Suppl 5):S386-S393. http://dx.doi.org/10.1086/533595.
6. American Thoracic Society; Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416. http://dx.doi.org/10.1164/rccm.200405-644ST.
7. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. 2010. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50:133-164. http://dx.doi.org/10.1086/649554.
8. Stevens DL, Bisno AL, Chambers HF, Dellinger PE, Goldstein EJC, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. 2014. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59:147-159. http://dx.doi.org/10.1093/cid/ciu444.
9. Woods GL, Washington JA. 1995. The clinician and the microbiology laboratory, p 169-199. In Mandell G, Bennett J, Dolin R (ed), Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, PA.
10. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256-265. http://dx.doi.org/10.1093/jac/dkl224.
11. Keel RA, Tessier PR, Crandon JL, Nicolau DP. 2012. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother 56:4403-4407. http://dx.doi.org/10.1128/AAC.00122-12.
12. Tessier PR, Nicolau DP. 2013. Tigecycline displays in vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period. Antimicrob Agents Chemother 57:640-642. http://dx.doi.org/10.1128/AAC.01824-12.
13. Crandon JL, Kuti JL, Nicolau DP. 2010. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother 54:5115-5119. http://dx.doi.org/10.1128/AAC.00062-10.
14. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 51:1481-1486. http://dx.doi.org/10.1128/AAC.00752-06.
15. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing: 24th informational supplement - document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Grossman TH, Murphy TM, Slee AM, Lofland D, Sutcliffe JA. 2015. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother 59:2567-2571. http://dx.doi.org/10.1128/AAC.04354-14.
17. Nathwani D. 2005. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 25:185-192. http://dx.doi.org/10.1016/j.ijantimicag.2004.11.006.
18. Schaper KJ, Schubert S, Dalhoff A. 2005. Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens. Infection 33(Suppl 2):3-14. http://dx.doi.org/10.1007/s15010-005-8202-2.
19. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44:1062-1066. http://dx.doi.org/10.1128/AAC.44.4.1062-1066.2000.
20. French GL. 2006. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J Antimicrob Chemother 58:1107-1117. http://dx.doi.org/10.1093/jac/dkl393.
21. Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. 2015. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 59:1802-1805. http://dx.doi.org/10.1128/AAC.04809-14.
22. Grossman TH, O'Brien W, Fyfe C, Sutcliffe JA. 2014. Eravacycline is potent against third generation cephalosporin- and carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and has isolate-specific bactericidal activity, abstr C-1374. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, San Diego, CA.
23. Thabit AK, Monogue ML, Nicolau DP. 2016. Eravacyclinepharmacokinetics and challenges in defining humanized exposure in vivo. Antimicrob Agents Chemother 60:5072-5075. http://dx.doi.org/10.1128/AAC.00240-16.